The purpose of a recent study published in Acta Dermatovenerologica Croatia was to determine the value of the innovative BIOCHIP mosaic-based indirect immunofluorescence (IF) technique in the diagnosis of pemphigus and bullous pemphigoid (BP) in Turkish patients. This study recruited 63 patients (45 pemphigus and 18 BP) in the active phase of the disease, and 35 healthy controls. All sera from patients and controls were tested using the BIOCHIP technique, and the results were compared with direct IF and/or enzyme-linked immunosorbent assay (ELISA). It was observed that the sensitivity and specificity of BIOCHIP in the diagnosis of pemphigus were found to be 91.1% and 97.1%, respectively. In addition, for the detection of anti-Dsg1 and anti-Dsg3 autoantibodies, the correlation between BIOCHIP and ELISA was statistically significant. Furthermore, the sensitivity and specificity of BIOCHIP in the diagnosis of BP were found to be 94.4% and 94.3%, respectively. In detection of anti-BP180 autoantibodies, the correlation between the BIOCHIP and ELISA was statistically significant. From the findings, it was concluded that the new BIOCHIP technique is a highly sensitive and specific tool in the diagnosis of pemphigus and BP.